{
    "nctId": "NCT01810393",
    "briefTitle": "A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years",
    "officialTitle": "An Open-Label, Randomized, Multicenter Phase III Study in Patients With HER2-Positive Metastatic Breast Cancer Responding to First Line Treatment With Intravenous Trastuzumab for at Least 3 Years and Investigating Patient Preference for Subcutaneous Trastuzumab",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 114,
    "primaryOutcomeMeasure": "Percentage of Participants With Preference for Either SC or IV Route of Administration According to Participant Preference Questionnaire (PPQ) Score",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed HER2-positive metastatic breast cancer\n* On treatment with first-line trastuzumab IV and free of disease progression for at least 3 years\n* Left ventricular ejection fraction (LVEF) of greater than or equal to (\\>/=) 50 percent (%)\n* Hormonal therapy will be allowed\n* Prior use of anti-HER2 therapy will be allowed\n\nExclusion Criteria:\n\n* History of other malignancy, except for curatively treated carcinoma in situ of the cervix or basal cell carcinoma and participants with other curatively treated malignancies who have been disease-free for at least 5 years; participants with previous ductal carcinoma in situ of the breast are also eligible\n* Participants with severe dyspnea at rest or requiring supplementary oxygen therapy\n* Serious cardiac illness or medical conditions that would preclude the use of trastuzumab\n* Hepatitis B, hepatitis C or human immunodeficiency virus infection\n* Pregnant or lactating women\n* Concurrent enrollment in an other clinical trial using an investigational anti-cancer treatment, including hormonal therapy, biphosphonate therapy and immunotherapy, within 28 days prior to the first dose of study treatment\n* Known hypersensitivity to trastuzumab, murine proteins, to any of the excipients of Herceptin including hyaluronidase or the adhesive of the subcutaneous device, or a history of severe allergic or immunological reactions, for example, difficult to control asthma\n* Central nervous system metastases, unless they have been treated and have been stable for at least 3 years\n* Inadequate organ function",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}